Ardelyx appoints J&J veteran Sue Hohenleitner as new CFO

WALTHAM, Mass. - Biopharmaceutical company Ardelyx, Inc. (NASDAQ:ARDX), currently valued at $1.19 billion and showing strong revenue growth of 84% over the last twelve months, announced today the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. According to InvestingPro analysis, the company maintains a GOOD financial health score, despite current market challenges.

Hohenleitner brings over 30 years of experience in corporate finance and will join Ardelyx following a 28-year career at Johnson & Johnson, where she most recently served as Vice President and Chief Financial Officer of J&J Innovative Medicine North America, overseeing financial strategies for a $36 billion commercial business.

"Sue is an accomplished and visionary financial leader whose proven ability to execute growth strategies and drive operational excellence makes her an exceptional addition to our company," said Mike Raab, president and chief executive officer of Ardelyx.

Hohenleitner will assume the CFO role after Ardelyx completes its third quarter 2025 financial reporting. Justin Renz, the current Chief Financial and Operations Officer, will continue in his position through the filing of the company’s Quarterly Report on Form 10-Q.

During her tenure at J&J, Hohenleitner led finance organizations across various functions including supply chain, innovation, commercial operations, and business development. She played a key role in acquisition deals that resulted in successful commercial launches.

A Certified Public Accountant in Pennsylvania and a Certified Management Accountant, Hohenleitner holds a Bachelor of Science in Accounting from La Salle University and an MBA from Villanova University.

Ardelyx currently markets two FDA-approved products in the United States: IBSRELA and XPHOZAH, both containing the active ingredient tenapanor. The company also has international commercialization agreements for tenapanor with partners in Japan, China, and Canada. With a gross profit margin of 71% and analyst price targets ranging from $8 to $15, detailed analysis and additional insights are available in the comprehensive Pro Research Report on InvestingPro, along with 10 key investment tips for ARDX.

The information in this article is based on a press release statement from Ardelyx.

In other recent news, Ardelyx, Inc reported its second-quarter 2025 earnings, showcasing a significant earnings surprise. The company posted a net loss of $0.08 per share, outperforming analysts’ expectations of a $0.13 loss. Revenue for the quarter reached $97.7 million, exceeding the forecast of $82.51 million, marking an 18.41% surprise. Additionally, Raymond James raised its price target for Ardelyx to $12.00 from $11.00, maintaining an Outperform rating due to strong sales figures for the company’s key products, Ibsrela and Xphozah. These sales figures surpassed consensus estimates, indicating a return to growth after a challenging first quarter. Furthermore, Raymond James reiterated its Strong Buy rating with a $14.00 price target following a court hearing regarding Ardelyx’s legal challenge against the Centers for Medicare & Medicaid Services. The case involves the inclusion of Ardelyx’s drug Xphozah in the Medicare Part B end-stage renal disease bundle payment system. These developments highlight the ongoing momentum and strategic challenges faced by Ardelyx.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.